Biotest Aktiengesellschaft (ETR: BIO)
Germany
· Delayed Price · Currency is EUR 41.40
0.00 (0.00%)
Dec 20, 2024, 5:36 PM CET
ETR: BIO Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 707 | 684.6 | 516.1 | 515.6 | 484.2 | 419.1 | Upgrade
|
| Revenue Growth (YoY) | 7.84% | 32.65% | 0.10% | 6.48% | 15.53% | 4.70% | Upgrade
|
| Cost of Revenue | 459.3 | 404.3 | 391.2 | 434.9 | 354.1 | 290.3 | Upgrade
|
| Gross Profit | 247.7 | 280.3 | 124.9 | 80.7 | 130.1 | 128.8 | Upgrade
|
| Selling, General & Admin | 84.9 | 84.4 | 81.9 | 82 | 79.5 | 82.5 | Upgrade
|
| Research & Development | 67.7 | 66.8 | 50.5 | 52.3 | 55.8 | 53.4 | Upgrade
|
| Other Operating Expenses | 25.1 | 12.4 | 12.7 | -2.7 | 2.4 | 6.1 | Upgrade
|
| Operating Expenses | 177.7 | 163.6 | 145.1 | 131.6 | 137.7 | 142 | Upgrade
|
| Operating Income | 70 | 116.7 | -20.2 | -50.9 | -7.6 | -13.2 | Upgrade
|
| Interest Expense | -31.8 | -36.6 | -18.5 | -12.4 | -13.1 | -9.1 | Upgrade
|
| Interest & Investment Income | - | 2 | 0.8 | 0.2 | 1.2 | 1.2 | Upgrade
|
| Earnings From Equity Investments | 2.8 | 2.8 | -1 | 1.3 | -0.5 | -0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.8 | -0.8 | 0.2 | -0.4 | -5.4 | -2.4 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.2 | -0.3 | -2.9 | -2.3 | -9.8 | 11.9 | Upgrade
|
| EBT Excluding Unusual Items | 40 | 83.8 | -41.6 | -64.5 | -35.2 | -11.7 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.9 | -0.9 | 8.4 | -1.2 | - | - | Upgrade
|
| Other Unusual Items | 15.5 | 23.2 | 1.1 | 1.1 | 5 | -0.1 | Upgrade
|
| Pretax Income | 54.8 | 106.3 | -30.9 | -62.7 | -30 | -1.3 | Upgrade
|
| Income Tax Expense | -13.7 | -20.7 | 0.8 | 0.7 | 1.4 | 3.4 | Upgrade
|
| Earnings From Continuing Operations | 68.5 | 127 | -31.7 | -63.4 | -31.4 | -4.7 | Upgrade
|
| Net Income to Company | 68.5 | 127 | -31.7 | -63.4 | -31.4 | -4.7 | Upgrade
|
| Net Income | 68.5 | 127 | -31.7 | -63.4 | -31.4 | -4.7 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.4 | Upgrade
|
| Net Income to Common | 68.5 | 127 | -31.7 | -63.4 | -31.4 | -5.1 | Upgrade
|
| Net Income Growth | -24.64% | - | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 40 | 40 | 40 | 40 | 40 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 40 | 40 | 40 | 40 | 40 | 40 | Upgrade
|
| Shares Change (YoY) | -0.87% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 1.73 | 3.21 | -0.80 | -1.60 | -0.79 | -0.13 | Upgrade
|
| EPS (Diluted) | 1.73 | 3.21 | -0.80 | -1.60 | -0.79 | -0.13 | Upgrade
|
| EPS Growth | -23.98% | - | - | - | - | - | Upgrade
|
| Free Cash Flow | 56.3 | -36.1 | -69.8 | 15.6 | -43.7 | -67.7 | Upgrade
|
| Free Cash Flow Per Share | 1.42 | -0.91 | -1.76 | 0.39 | -1.10 | -1.71 | Upgrade
|
| Dividend Per Share | 0.040 | 0.040 | - | 0.040 | 0.040 | 0.040 | Upgrade
|
| Gross Margin | 35.04% | 40.94% | 24.20% | 15.65% | 26.87% | 30.73% | Upgrade
|
| Operating Margin | 9.90% | 17.05% | -3.91% | -9.87% | -1.57% | -3.15% | Upgrade
|
| Profit Margin | 9.69% | 18.55% | -6.14% | -12.30% | -6.48% | -1.22% | Upgrade
|
| Free Cash Flow Margin | 7.96% | -5.27% | -13.52% | 3.03% | -9.03% | -16.15% | Upgrade
|
| EBITDA | 100.25 | 147.1 | 10.4 | -24.8 | 17.3 | 11.4 | Upgrade
|
| EBITDA Margin | 14.18% | 21.49% | 2.02% | -4.81% | 3.57% | 2.72% | Upgrade
|
| D&A For EBITDA | 30.25 | 30.4 | 30.6 | 26.1 | 24.9 | 24.6 | Upgrade
|
| EBIT | 70 | 116.7 | -20.2 | -50.9 | -7.6 | -13.2 | Upgrade
|
| EBIT Margin | 9.90% | 17.05% | -3.91% | -9.87% | -1.57% | -3.15% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.